Completed PHASE2 INTERVENTIONAL 2-arm NCT01110057

Efficacy Study in Lumbosacral Radiculopathy

A Randomised, Double Blind Study to Evaluate the Safety and Efficacy of the p38 Kinase Inhibitor, GW856553, in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Sponsor: GlaxoSmithKline

Conditions Pain, Neuropathic

Interventions GS856553 Placebo

Updated 7 times since 2017 Last updated: Jun 7, 2017 Started: Jan 7, 2010 Primary completion: Aug 23, 2010 Completion: Aug 23, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pain, Neuropathic and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Jun 2017 [monthly]

Completed PHASE2

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bois-Guillaume, France , Boulogne-Billancourt, France , Hamar, Norway , Hamburg, Germany , Hoersholm, Denmark , Leipzg, Germany , Lyon, France , Munich, Germany , Nice, France , Odense C, Denmark and 6 more locations